Rivastigmine: new indication. Dementia and Parkinson's disease: no thank you!
In patients with both Parkinson's disease and dementia, a placebo-controlled trial has confirmed that the adverse effects of rivastigmine outweigh its benefits. It is better to carefully adjust ongoing antiparkinsonian treatments than to add an anticholinesterase.
D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003704:Dementia / Q000188:drug therapy*; D005060:Europe; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy*; D048448:Phenylcarbamates / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates